Dr Agarwals Eye Hospital profit and loss

Latest FY26

Revenue: ₹471cr+18.6% on FY25
EBITDA: ₹145cr+22.6% on FY25
Net profit: ₹70.1cr+28.3% on FY25
EPS: ₹147.02+26.4% on FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	471	397	319	268	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	5.8	5.1	5.0	1.8
	477	402	324	270
	47.7	43.1	36.0	30.7
	91.7	78.3	63.8	53.3
	11.9	13.4	7.2	6.9
	45.6	39.5	26.6	20.2
	71.0	57.4	45.5	110
	383	332	262	220
	145	119	91.1	74.7
	99.7	79.1	64.5	54.5
Profit
	93.6	70.7	62.3	49.4
	10.1	—	10.1	12.3
	10.1	10.1	10.1	0.2
	23.5	16.1	15.9	12.5
	70.1	54.7	46.4	36.9
	0.0	0.2	—	—
	70.1	54.8	46.4	36.6
Per share
	₹147.02	₹116.28	₹98.64	₹78.55
	₹147.02	₹116.28	₹98.64	₹78.55
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	423	354	283	237
	89.9%	89.1%	88.7%	88.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersKMCSHIL KOVAI LOTUSEYE GPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMEDMcap ₹2,527 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Revenue from Operations	267.9	319.3	397.2	470.9
Other Income	1.8	5.0	5.1	5.8
Total Income	269.7	324.3	402.2	476.7
Expenses
+ Purchases of Stock-in-Trade	30.7	36.0	43.1	47.7
+ Employee Benefit Expense	53.3	63.8	78.3	91.7
+ Finance Costs	6.9	7.2	13.4	11.9
+ Depreciation & Amortisation	20.2	26.6	39.5	45.6
+ Other Expenses	110.1	45.5	57.4	71.0
Total Expenses	220.3	262.0	331.5	383.1
EBITDA	74.7	91.1	118.5	145.3
EBIT	54.5	64.5	79.1	99.7
Profit
Pretax Income	49.4	62.3	70.7	93.6
+ Current Tax	12.3	10.1	—	10.1
+ Deferred Tax	0.2	10.1	10.1	10.1
Tax Expense	12.5	15.9	16.1	23.5
Net Income	36.9	46.4	54.7	70.1
+ Other Comprehensive Income	—	—	0.2	0.0
Total Comprehensive Income	36.6	46.4	54.8	70.1
Per Share
Basic EPS	78.55	98.64	116.28	147.02
Diluted EPS	78.55	98.64	116.28	147.02
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	237.2	283.4	354.0	423.1
Gross Margin %	88.55	88.74	89.15	89.86

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.